<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04543643</url>
  </required_header>
  <id_info>
    <org_study_id>Tianjin2PH</org_study_id>
    <nct_id>NCT04543643</nct_id>
  </id_info>
  <brief_title>Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis</brief_title>
  <acronym>CABER</acronym>
  <official_title>Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis: a Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Second People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carvedilol has been shown to be more potent in decreasing portal hypertension to propranolol.&#xD;
      A lot of studies have shown that the imbalance of flora and the progress of portal&#xD;
      hypertension are mutually causal. Berberine can regulate the intestinal flora.In this study,&#xD;
      we evaluated the effect of carvedilol and berberine on reducing portal vein pressure by&#xD;
      observing the changes of endoscopy，endoscopic ultrasonography and intestinal flora.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a higher risk of esophageal and gastric varices bleeding in cirrhosis patients with&#xD;
      moderate and severe esophageal and gastric varices. Once there is a high mortality rate of&#xD;
      esophageal and gastric varices bleeding, it will cause great losses to the family and&#xD;
      society. Therefore, it is of great social and economic significance to prevent esophageal and&#xD;
      gastric varices bleeding through economic and effective methods. As the third generation of&#xD;
      NSBB, carvedilol is more effective in reducing HVPG than propranolol, which is recommended by&#xD;
      Baveno VI as the first-line drug for EVB primary prevention. A lot of studies have shown that&#xD;
      the imbalance of flora and the progress of portal hypertension are mutually causal. The&#xD;
      application of carvedilol can reduce the pressure of portal vein, and when the portal&#xD;
      hypertension is improved, the imbalance of intestinal mucosal barrier and flora will also be&#xD;
      changed. Berberine can regulate the intestinal flora, which is safe and effective in clinical&#xD;
      application. Gastroscopy is still the main method of screening varicose veins. We can&#xD;
      determine whether there is GOV in patients and evaluate the risk of varicose vein bleeding.&#xD;
      However, gastroscopy can only observe the situation in the digestive tract lumen, and&#xD;
      ultrasound endoscopy can scan the outside of the tube wall, so as to more comprehensively&#xD;
      evaluate the change of portal hypertension. The purpose of this study is to apply endoscopic&#xD;
      ultrasonography to the whole process of the study, which can be used as a more sensitive&#xD;
      means to observe the changes of portal hypertension, and to systematically evaluate the&#xD;
      continuous changes of portal hypertension. It provides a theoretical basis and measurement&#xD;
      means for a more comprehensive and scientific evaluation of portal hypertension.In this&#xD;
      study, the patients with GOV who need primary prevention were randomly divided into two&#xD;
      groups. Carvedilol or carvedilol combined with berberine were given for 12 months&#xD;
      respectively. The degree of varicose vein relief was judged by ES and EUS, and the changes of&#xD;
      oral and intestinal flora were detected at the same time To understand the possible mechanism&#xD;
      of carvedilol and berberine in reducing portal hypertension.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The progression Incidence of esophageal varices</measure>
    <time_frame>1 year</time_frame>
    <description>progression of esophagogastric varices under gastroscopy and/or endoscopic ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of liver cirrhosis decompensation</measure>
    <time_frame>1 year</time_frame>
    <description>the occurrence of decompensating events in cirrhosis (decompensating is defined as gastrointestinal bleeding, ascites, or significant hepatic encephalopathy, hepatorenal syndrome, associated with portal hypertension)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCC, death or liver transplantation</measure>
    <time_frame>1 year</time_frame>
    <description>The incidence of hepatic cellular carcinoma, death or liver transplantation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Cirrhosis Due to Hepatitis B</condition>
  <condition>Cirrhosis Due to Hepatitis C</condition>
  <condition>Gastroesophageal Varices</condition>
  <arm_group>
    <arm_group_label>Carvedilol+ berberine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carvedilol is started at a dose of 6.25 mg once per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day if systolic blood pressure does not fall below 85mm Hg and HR 55/min. Berberine is started at a dose of 0.3g twice per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carvedilol is started at a dose of 6.25 mg once per day. After 1 week, this will increased to a dose of 6.25 mg twice daily per day if systolic blood pressure does not fall below 85 mm Hg and HR 55/min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>As the third generation of NSBB, carvedilol is more effective in reducing HVPG than propranolol, which is recommended by Baveno VI as the first-line drug for EVB primary prevention.</description>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_label>Carvedilol+ berberine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berberine</intervention_name>
    <description>Berberine can regulate the intestinal flora, which is safe and effective in clinical application.</description>
    <arm_group_label>Carvedilol+ berberine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HBV-related or/and HCV-related liver cirrhotic patients based on pathology or clinical&#xD;
             diagnosis;&#xD;
&#xD;
               -  Antiviral therapy;&#xD;
&#xD;
               -  Male or Female;&#xD;
&#xD;
               -  ES showed the presence of esophageal and gastric varices and / or red signs;&#xD;
&#xD;
               -  Child-Pugh &lt; 10, and meld &lt; 29;&#xD;
&#xD;
               -  Signature of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Used antibiotics, prebiotics, probiotics and proton pump inhibitors within 2 weeks;&#xD;
&#xD;
               -  Any contra-indications to beta-blockers including asthma, chronic obstructive&#xD;
                  pulmonary disease, allergic rhinitis, NYHA (New York Heart Association) class IV&#xD;
                  heart failure, atrioventricular block, sinus bradycardia (HR &lt; 50 / min),&#xD;
                  cardiogenic shock, hypotension (SBP &lt; 85mmHg), sick sinus syndrome, insulin&#xD;
                  dependent diabetes, peripheral vascular disease;&#xD;
&#xD;
               -  Unstable high blood pressure and long-term engagement in driving;&#xD;
&#xD;
               -  Any malignancy that affects survival, excluding the cured;&#xD;
&#xD;
               -  Patients with portal thrombosis;&#xD;
&#xD;
               -  PT extension greater than 4 seconds, PLT&lt;30×10^9/L;&#xD;
&#xD;
               -  Pregnant and lactating patients;&#xD;
&#xD;
               -  History of surgery for portal hypertension；History of prior EVL (endoscopic&#xD;
                  variceal ligation) or sclerotherapy, history of surgery for portal hypertension&#xD;
                  including portosystemic shunts, disconnection and spleen resection and&#xD;
                  transjugular intrahepatic portosystemic shunt;&#xD;
&#xD;
               -  Patients with severe diseases of vital organs such as heart, lung, kidney, brain,&#xD;
                  blood and nervous system;&#xD;
&#xD;
               -  Allergic to carvedilol and berberine;&#xD;
&#xD;
               -  Severe systemic diseases；&#xD;
&#xD;
               -  hemolytic anemia and lack of glucose - 6 - phosphate dehydrogenase patients&#xD;
&#xD;
               -  Refusal to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Han Ping, bachelor</last_name>
    <phone>13652139315</phone>
    <email>13652139315@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Jia, professor</last_name>
    <phone>13302106853</phone>
    <email>18622663700@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tianjin Second People's Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300192</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Han Ping, bachelor</last_name>
      <phone>+8613652139315</phone>
      <email>13652139315@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Li Jia, professor</last_name>
      <phone>+86133021006853</phone>
      <email>18622663700@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med. 1988 Oct 13;319(15):983-9.</citation>
    <PMID>3262200</PMID>
  </results_reference>
  <results_reference>
    <citation>Carbonell N, Pauwels A, Serfaty L, Fourdan O, Lévy VG, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology. 2004 Sep;40(3):652-9.</citation>
    <PMID>15349904</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang X, Lin SX, Tao J, Wei XQ, Liu YT, Chen YM, Wu B. Study of liver cirrhosis over ten consecutive years in Southern China. World J Gastroenterol. 2014 Oct 7;20(37):13546-55. doi: 10.3748/wjg.v20.i37.13546.</citation>
    <PMID>25309085</PMID>
  </results_reference>
  <results_reference>
    <citation>de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015 Sep;63(3):743-52. doi: 10.1016/j.jhep.2015.05.022. Epub 2015 Jun 3.</citation>
    <PMID>26047908</PMID>
  </results_reference>
  <results_reference>
    <citation>Abadía M, Montes ML, Ponce D, Froilán C, Romero M, Poza J, Hernández T, Fernández-Martos R, Olveira A; &quot;La Paz Portal Hypertension&quot; Study Group Investigators. Management of betablocked patients after sustained virological response in hepatitis C cirrhosis. World J Gastroenterol. 2019 Jun 7;25(21):2665-2674. doi: 10.3748/wjg.v25.i21.2665.</citation>
    <PMID>31210717</PMID>
  </results_reference>
  <results_reference>
    <citation>Hammoud GM, Ibdah JA. Utility of endoscopic ultrasound in patients with portal hypertension. World J Gastroenterol. 2014 Oct 21;20(39):14230-6. doi: 10.3748/wjg.v20.i39.14230. Review.</citation>
    <PMID>25339809</PMID>
  </results_reference>
  <results_reference>
    <citation>Hashizume M, Kitano S, Sugimachi K, Sueishi K. Three-dimensional view of the vascular structure of the lower esophagus in clinical portal hypertension. Hepatology. 1988 Nov-Dec;8(6):1482-7.</citation>
    <PMID>3192160</PMID>
  </results_reference>
  <results_reference>
    <citation>Huang JY, Samarasena JB, Tsujino T, Chang KJ. EUS-guided portal pressure gradient measurement with a novel 25-gauge needle device versus standard transjugular approach: a comparison animal study. Gastrointest Endosc. 2016 Aug;84(2):358-62. doi: 10.1016/j.gie.2016.02.032. Epub 2016 Mar 3.</citation>
    <PMID>26945557</PMID>
  </results_reference>
  <results_reference>
    <citation>Tripathi D, Ferguson JW, Kochar N, Leithead JA, Therapondos G, McAvoy NC, Stanley AJ, Forrest EH, Hislop WS, Mills PR, Hayes PC. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology. 2009 Sep;50(3):825-33. doi: 10.1002/hep.23045.</citation>
    <PMID>19610055</PMID>
  </results_reference>
  <results_reference>
    <citation>Reiberger T, Ulbrich G, Ferlitsch A, Payer BA, Schwabl P, Pinter M, Heinisch BB, Trauner M, Kramer L, Peck-Radosavljevic M; Vienna Hepatic Hemodynamic Lab. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut. 2013 Nov;62(11):1634-41. doi: 10.1136/gutjnl-2012-304038. Epub 2012 Dec 18.</citation>
    <PMID>23250049</PMID>
  </results_reference>
  <results_reference>
    <citation>Bhardwaj A, Kedarisetty CK, Vashishtha C, Bhadoria AS, Jindal A, Kumar G, Choudhary A, Shasthry SM, Maiwall R, Kumar M, Bhatia V, Sarin SK. Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial. Gut. 2017 Oct;66(10):1838-1843. doi: 10.1136/gutjnl-2016-311735. Epub 2016 Jun 13.</citation>
    <PMID>27298379</PMID>
  </results_reference>
  <results_reference>
    <citation>Borzio M, Salerno F, Piantoni L, Cazzaniga M, Angeli P, Bissoli F, Boccia S, Colloredo-Mels G, Corigliano P, Fornaciari G, Marenco G, Pistarà R, Salvagnini M, Sangiovanni A. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis. 2001 Jan-Feb;33(1):41-8.</citation>
    <PMID>11303974</PMID>
  </results_reference>
  <results_reference>
    <citation>Pascual S, Such J, Esteban A, Zapater P, Casellas JA, Aparicio JR, Girona E, Gutiérrez A, Carnices F, Palazón JM, Sola-Vera J, Pérez-Mateo M. Intestinal permeability is increased in patients with advanced cirrhosis. Hepatogastroenterology. 2003 Sep-Oct;50(53):1482-6.</citation>
    <PMID>14571769</PMID>
  </results_reference>
  <results_reference>
    <citation>García-Tsao G. Bacterial translocation: cause or consequence of decompensation in cirrhosis? J Hepatol. 2001 Jan;34(1):150-5.</citation>
    <PMID>11211893</PMID>
  </results_reference>
  <results_reference>
    <citation>Arvaniti V, D'Amico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M, Burroughs AK. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010 Oct;139(4):1246-56, 1256.e1-5. doi: 10.1053/j.gastro.2010.06.019. Epub 2010 Jun 14.</citation>
    <PMID>20558165</PMID>
  </results_reference>
  <results_reference>
    <citation>Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs AK. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology. 1998 May;27(5):1207-12.</citation>
    <PMID>9581672</PMID>
  </results_reference>
  <results_reference>
    <citation>Thalheimer U, Triantos CK, Samonakis DN, Patch D, Burroughs AK. Infection, coagulation, and variceal bleeding in cirrhosis. Gut. 2005 Apr;54(4):556-63. Review.</citation>
    <PMID>15753544</PMID>
  </results_reference>
  <results_reference>
    <citation>Reiberger T, Ferlitsch A, Payer BA, Mandorfer M, Heinisch BB, Hayden H, Lammert F, Trauner M, Peck-Radosavljevic M, Vogelsang H; Vienna Hepatic Hemodynamic Lab. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013 May;58(5):911-21. doi: 10.1016/j.jhep.2012.12.011. Epub 2012 Dec 20.</citation>
    <PMID>23262249</PMID>
  </results_reference>
  <results_reference>
    <citation>Adamberg K, Tomson K, Talve T, Pudova K, Puurand M, Visnapuu T, Alamäe T, Adamberg S. Levan Enhances Associated Growth of Bacteroides, Escherichia, Streptococcus and Faecalibacterium in Fecal Microbiota. PLoS One. 2015 Dec 2;10(12):e0144042. doi: 10.1371/journal.pone.0144042. eCollection 2015.</citation>
    <PMID>26629816</PMID>
  </results_reference>
  <results_reference>
    <citation>Yao J, Chang L, Yuan L, Duan Z. Nutrition status and small intestinal bacterial overgrowth in patients with virus-related cirrhosis. Asia Pac J Clin Nutr. 2016;25(2):283-91. doi: 10.6133/apjcn.2016.25.2.06.</citation>
    <PMID>27222411</PMID>
  </results_reference>
  <results_reference>
    <citation>Hoyles L, Fernández-Real JM, Federici M, Serino M, Abbott J, Charpentier J, Heymes C, Luque JL, Anthony E, Barton RH, Chilloux J, Myridakis A, Martinez-Gili L, Moreno-Navarrete JM, Benhamed F, Azalbert V, Blasco-Baque V, Puig J, Xifra G, Ricart W, Tomlinson C, Woodbridge M, Cardellini M, Davato F, Cardolini I, Porzio O, Gentileschi P, Lopez F, Foufelle F, Butcher SA, Holmes E, Nicholson JK, Postic C, Burcelin R, Dumas ME. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat Med. 2018 Jul;24(7):1070-1080. doi: 10.1038/s41591-018-0061-3. Epub 2018 Jun 25. Erratum in: Nat Med. 2018 Aug 9;:.</citation>
    <PMID>29942096</PMID>
  </results_reference>
  <results_reference>
    <citation>Silva Santos PS, Fernandes KS, Gallottini MH. Assessment and management of oral health in liver transplant candidates. J Appl Oral Sci. 2012 Mar-Apr;20(2):241-5.</citation>
    <PMID>22666844</PMID>
  </results_reference>
  <results_reference>
    <citation>Aberg F, Helenius-Hietala J, Meurman J, Isoniemi H. Association between dental infections and the clinical course of chronic liver disease. Hepatol Res. 2014 Mar;44(3):349-53. doi: 10.1111/hepr.12126. Epub 2013 Apr 29.</citation>
    <PMID>23607641</PMID>
  </results_reference>
  <results_reference>
    <citation>Bajaj JS, Betrapally NS, Hylemon PB, Heuman DM, Daita K, White MB, Unser A, Thacker LR, Sanyal AJ, Kang DJ, Sikaroodi M, Gillevet PM. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy. Hepatology. 2015 Oct;62(4):1260-71. doi: 10.1002/hep.27819. Epub 2015 May 6.</citation>
    <PMID>25820757</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang Y, Shou JW, Li XY, Zhao ZX, Fu J, He CY, Feng R, Ma C, Wen BY, Guo F, Yang XY, Han YX, Wang LL, Tong Q, You XF, Lin Y, Kong WJ, Si SY, Jiang JD. Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism. Metabolism. 2017 May;70:72-84. doi: 10.1016/j.metabol.2017.02.003. Epub 2017 Feb 10.</citation>
    <PMID>28403947</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen YX, Gao QY, Zou TH, Wang BM, Liu SD, Sheng JQ, Ren JL, Zou XP, Liu ZJ, Song YY, Xiao B, Sun XM, Dou XT, Cao HL, Yang XN, Li N, Kang Q, Zhu W, Xu HZ, Chen HM, Cao XC, Fang JY. Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. Lancet Gastroenterol Hepatol. 2020 Mar;5(3):267-275. doi: 10.1016/S2468-1253(19)30409-1. Epub 2020 Jan 8.</citation>
    <PMID>31926918</PMID>
  </results_reference>
  <results_reference>
    <citation>Mandorfer M, Peck-Radosavljevic M, Reiberger T. Prevention of progression from small to large varices: are we there yet? An updated meta-analysis. Gut. 2017 Jul;66(7):1347-1349. doi: 10.1136/gutjnl-2016-312814. Epub 2016 Sep 30.</citation>
    <PMID>27694143</PMID>
  </results_reference>
  <results_reference>
    <citation>Sharma M, Singh S, Desai V, Shah VH, Kamath PS, Murad MH, Simonetto DA. Comparison of Therapies for Primary Prevention of Esophageal Variceal Bleeding: A Systematic Review and Network Meta-analysis. Hepatology. 2019 Apr;69(4):1657-1675. doi: 10.1002/hep.30220. Epub 2019 Feb 20.</citation>
    <PMID>30125369</PMID>
  </results_reference>
  <results_reference>
    <citation>Shah HA, Azam Z, Rauf J, Abid S, Hamid S, Jafri W, Khalid A, Ismail FW, Parkash O, Subhan A, Munir SM. Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial. J Hepatol. 2014 Apr;60(4):757-64. doi: 10.1016/j.jhep.2013.11.019. Epub 2013 Nov 28.</citation>
    <PMID>24291366</PMID>
  </results_reference>
  <results_reference>
    <citation>Schwarzer R, Kivaranovic D, Paternostro R, Mandorfer M, Reiberger T, Trauner M, Peck-Radosavljevic M, Ferlitsch A. Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study. Aliment Pharmacol Ther. 2018 Apr;47(8):1162-1169. doi: 10.1111/apt.14576. Epub 2018 Feb 28.</citation>
    <PMID>29492989</PMID>
  </results_reference>
  <results_reference>
    <citation>Ding Q, Tian XG, Li Y, Wang QZ, Zhang CQ. Carvedilol may attenuate liver cirrhosis by inhibiting angiogenesis through the VEGF-Src-ERK signaling pathway. World J Gastroenterol. 2015 Aug 28;21(32):9566-76. doi: 10.3748/wjg.v21.i32.9566.</citation>
    <PMID>26327764</PMID>
  </results_reference>
  <results_reference>
    <citation>Gupta N, Kumar A, Sharma P, Garg V, Sharma BC, Sarin SK. Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial. Liver Int. 2013 Sep;33(8):1148-57. doi: 10.1111/liv.12172. Epub 2013 Apr 21.</citation>
    <PMID>23601333</PMID>
  </results_reference>
  <results_reference>
    <citation>Kakiyama G, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, Takei H, Muto A, Nittono H, Ridlon JM, White MB, Noble NA, Monteith P, Fuchs M, Thacker LR, Sikaroodi M, Bajaj JS. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol. 2013 May;58(5):949-55. doi: 10.1016/j.jhep.2013.01.003. Epub 2013 Jan 16.</citation>
    <PMID>23333527</PMID>
  </results_reference>
  <results_reference>
    <citation>Szabo G. Gut-liver axis in alcoholic liver disease. Gastroenterology. 2015 Jan;148(1):30-6. doi: 10.1053/j.gastro.2014.10.042. Epub 2014 Nov 11. Review.</citation>
    <PMID>25447847</PMID>
  </results_reference>
  <results_reference>
    <citation>Seo YS, Shah VH. The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension. Clin Mol Hepatol. 2012 Dec;18(4):337-46. doi: 10.3350/cmh.2012.18.4.337. Epub 2012 Dec 21. Review.</citation>
    <PMID>23323248</PMID>
  </results_reference>
  <results_reference>
    <citation>Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015 Nov;63(5):1272-84. doi: 10.1016/j.jhep.2015.07.004. Epub 2015 Jul 17. Review.</citation>
    <PMID>26192220</PMID>
  </results_reference>
  <results_reference>
    <citation>Moghadamrad S, McCoy KD, Geuking MB, Sägesser H, Kirundi J, Macpherson AJ, De Gottardi A. Attenuated portal hypertension in germ-free mice: Function of bacterial flora on the development of mesenteric lymphatic and blood vessels. Hepatology. 2015 May;61(5):1685-95. doi: 10.1002/hep.27698. Epub 2015 Feb 24.</citation>
    <PMID>25643846</PMID>
  </results_reference>
  <results_reference>
    <citation>García-Lezana T, Raurell I, Bravo M, Torres-Arauz M, Salcedo MT, Santiago A, Schoenenberger A, Manichanh C, Genescà J, Martell M, Augustin S. Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis. Hepatology. 2018 Apr;67(4):1485-1498. doi: 10.1002/hep.29646. Epub 2018 Feb 19.</citation>
    <PMID>29113028</PMID>
  </results_reference>
  <results_reference>
    <citation>European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018 Aug;69(2):461-511. doi: 10.1016/j.jhep.2018.03.026. Epub 2018 Apr 9.</citation>
    <PMID>29650333</PMID>
  </results_reference>
  <results_reference>
    <citation>Feng R, Shou JW, Zhao ZX, He CY, Ma C, Huang M, Fu J, Tan XS, Li XY, Wen BY, Chen X, Yang XY, Ren G, Lin Y, Chen Y, You XF, Wang Y, Jiang JD. Transforming berberine into its intestine-absorbable form by the gut microbiota. Sci Rep. 2015 Jul 15;5:12155. doi: 10.1038/srep12155.</citation>
    <PMID>26174047</PMID>
  </results_reference>
  <results_reference>
    <citation>Koren O, Goodrich JK, Cullender TC, Spor A, Laitinen K, Bäckhed HK, Gonzalez A, Werner JJ, Angenent LT, Knight R, Bäckhed F, Isolauri E, Salminen S, Ley RE. Host remodeling of the gut microbiome and metabolic changes during pregnancy. Cell. 2012 Aug 3;150(3):470-80. doi: 10.1016/j.cell.2012.07.008.</citation>
    <PMID>22863002</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 3, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gastroesophageal varices</keyword>
  <keyword>cirrhosis</keyword>
  <keyword>carvedilol</keyword>
  <keyword>berberine</keyword>
  <keyword>Endoscopic ultrasonography</keyword>
  <keyword>gut microbiota</keyword>
  <keyword>portal hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

